Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus

被引:28
|
作者
Kuranov, S. O. [1 ]
Tsypysheva, I. P. [2 ]
Khvostov, M., V [1 ,5 ]
Zainullina, Liana F. [3 ,4 ]
Borisevich, S. S. [2 ]
Vakhitova, Yu V. [3 ,4 ]
Luzina, O. A. [1 ]
Salakhutdinov, N. F. [1 ,5 ]
机构
[1] Russian Acad Sci, Siberian Branch, NN Vorozhtsov Novosibirsk Inst Organ Chem, Novosibirsk 630090, Russia
[2] Russian Acad Sci, Ufa Inst Chem, Ufa 450054, Russia
[3] FSBI Zalcusov Inst Pharmacol, Moscow 125315, Russia
[4] IBG UFRC RAS, Ufa 450054, Russia
[5] Novosibirsk State Univ, Novosibirsk 630090, Russia
关键词
DIPEPTIDYL-PEPTIDASE-IV; COMPLICATIONS; EPIDEMIOLOGY; DERIVATIVES; INSULIN; DESIGN; POTENT; DRUGS;
D O I
10.1016/j.bmc.2018.07.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study, bornyl- and cytisine-based cyanopyrrolidines as potent dipeptidyl peptidase-IV (DPP-IV) inhibitors were synthesised. The in vitro inhibiting activities of bornyl- and cytisine derivatives towards DPP-IV were evaluated. Bornyl-based cyanopyrrolidines were shown to have moderate inhibitory activity with regard to DPP-IV (1.27-15.78 mu M). A docking study was performed to elucidate the structure-activity relationship of the obtained compounds. The in vivo hypoglycemic activities of the same compounds were evaluated with the oral glucose tolerance test (OGTT) in mice. Bornyl-based cyanopyrrolidines were shown to have good hypoglycemic activity.
引用
收藏
页码:4402 / 4409
页数:8
相关论文
共 50 条
  • [31] GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors
    Ahrén B.
    Current Diabetes Reports, 2007, 7 (5) : 340 - 347
  • [32] In silico Studies on the Interaction Between Bioactive Ligands and DPP-IV: Insights on Potential Candidates for the Treatment of type 2 Diabetes Mellitus
    Martins, Michelle C. M. R.
    Pantaleao, Simone Q.
    Almeida, Michell de Oliveira
    Weber, Karen C.
    Honorio, Kathia M.
    MEDICINAL CHEMISTRY, 2021, 17 (03) : 247 - 263
  • [33] Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes
    Singh, Anand-Krishna
    Jatwa, Rameshwar
    Purohit, Ashok
    Ram, Heera
    JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH, 2017, 19 (10) : 1036 - 1045
  • [34] Incretin mimetics and DPP-IV inhibitors: New paradigms for the treatment of type 2 diabetes (vol 19, pg 612, 2006)
    Hinnen, D.
    Nielsen, L. L.
    Waninger, A.
    Kushner, P.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2007, 20 (02) : 240 - 240
  • [35] DPP-IV Inhibitors from natural sources: An alternative approach for treatment and management of diabetes
    Sharma, Divya
    Kumar, Sandeep
    Kumar, Sunil
    Kumar, Dinesh
    INDIAN JOURNAL OF NATURAL PRODUCTS AND RESOURCES, 2019, 10 (04): : 227 - 237
  • [36] Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV(DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective
    Kushwaha, R. N.
    Haq, W.
    Katti, S. B.
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (35) : 4013 - 4045
  • [37] Synthesis, Biological Evaluation, and QPLD Studies of Piperazine Derivatives as Potential DPP-IV Inhibitors
    Abu Khalaf, Reema
    Abu Jarad, Haya
    Al-Qirim, Tariq
    Sabbah, Dima
    MEDICINAL CHEMISTRY, 2021, 17 (09) : 937 - 944
  • [38] Phenanthridine Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Design, Synthesis and Biological Evaluation
    Abu Khalaf, Reema
    Alqazaqi, Shorooq
    Aburezeq, Maram
    Sabbah, Dima
    Albadawi, Ghadeer
    Abu Sheikha, Ghassan
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2022, 18 (01) : 9 - 25
  • [39] In Silico ADMET Evaluation of Natural DPP-IV Inhibitors for Rational Drug Design against Diabetes
    Singla, Rajeev K.
    Shen, Bairong
    CURRENT DRUG METABOLISM, 2020, 21 (10) : 768 - 777
  • [40] Indole Alkaloids as New Leads for the Design and Development of Novel DPP-IV Inhibitors for the Treatment of Diabetes
    Dhiraviam, Kannan Narayanan
    Balasubramanian, Suganthana
    Jayavel, Sridhar
    CURRENT BIOINFORMATICS, 2018, 13 (02) : 157 - 169